



MICROPHAGE

News Release

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

MicroPhage, Inc. appoints Alene A. Campbell as CEO

LONGMONT, Colo., March 18, 2010—[MicroPhage](#) announced today that it has appointed **Alene A. Campbell** as its chief executive officer, effective immediately. Ms. Campbell, who has served MicroPhage for the past two years as its Chief Operations Officer, replaces Steve Lundy, who has resigned.

Ms. Campbell joined MicroPhage in 2008 as COO and, in that role, has directed finance, research and development, manufacturing, quality assurance, human resources, product development as well as clinical affairs efforts and staff at MicroPhage. She has held executive positions in the biotechnology, diagnostic, and pharmaceutical industries for over 28 years.

“This is a very exciting time for MicroPhage,” said Ms. Campbell. “The recent submission of our pivotal study data to the FDA for clearance to market our first test in the United States marks a seminal event in the development of MicroPhage’s **platform technology**.”

Ms. Campbell previously served as Vice President of Corporate Development at Myogen (now Gilead); General Manager of RPI/SiRNA (now Merck); Executive Vice President, CFO, and Vice President Marketing and Sales of ChemTrak (a Bay Area diagnostics firm, overseeing its IPO, manufacturing scale-up, product launch, strategic partnering, market and sales); and Vice President of Hana Biologics (now BioSante). She holds an MBA from the University of California, Berkeley.

“Ms. Campbell’s experience and successful history with MicroPhage makes the Board comfortable to appoint her to this position,” said MicroPhage Chairman R. Gary Mesch. “We are happy to have her aboard to take the reins in this exciting time of growth for MicroPhage.”

The company recently announced that it has submitted human data from a pivotal clinical study of its ‘**Microphage MRSA/MSSA Blood Culture Test - BT**’ to support a U.S. Food and Drug Administration (FDA) **510(k) premarket notification** application. The first of MicroPhage’s instrument-free, rapid tests is based on the Company’s patented ***Bacteriophage Amplification*** platform technology. MicroPhage has already begun international commercial shipments of this test—which has already received European regulatory clearance (CE Mark). The Test is designed to rapidly identify ***Staphylococcus aureus*** (“staph”) bacteria and determine methicillin resistance (**MRSA**) or susceptibility (**MSSA**) in suspected cases of bacteremia—bacteria in the blood—**in as little as five hours**. Today’s standard of care for determining these types of infections takes up to three days for test-results, which can result in ineffective treatment, increased bacterial resistance, and death.

About MicroPhage, Inc.

Based in Longmont, Colorado, privately held MicroPhage is working to be a global leader in developing rapid, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary ***Bacteriophage Amplification*** platform, the Company has developed a patented process that is a product platform for rapid, easy-to-use, inexpensive diagnostic and screening tests. The technology platform resembles a home pregnancy test with twin, rapid detectors. The platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.